Testing a wearable compression device for moderate to severe irritable bowel syndrome
Tests a wearable compression device in adults with moderate to severe irritable bowel syndrome.
Key facts
- Who runs it
- PGP Health
- Where
- Bolingbrook, Kissimmee, and Southhaven, United StatesSee the 3 sites
- Trial code
- Registry title
- A Prospective Trial of a Variable Compression System for Moderate to Severe Irritable Bowel Syndrome
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 21 May 2025
- Planned end
- 1 May 2026
- Type of study
- Interventional
- Treatments tested
- Variable Compression System
- Record updated
- 29 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe irritable bowel syndrome (IBS). They will wear a compression device for at least 6 hours a day.
- Age
- 18 Years to 60 Years
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe IBS, diagnosed by the Rome Criteria. This can be the constipation type (IBS-C), the diarrhea type (IBS-D) or the mixed type (IBS-M).
- Earlier treatment
- People who took part in another trial of an investigational drug within 30 days before screening cannot join.
- Biomarker or test result
- Weight of ≥50 kg (110 lb) and a body mass index between 18 and 40 kg/m2.
Main reasons for not taking part
- Allergy to the device or its parts, or serious allergies (mild seasonal allergies are allowed)
- Hospital stay or major surgery within 30 days before screening
- Being pregnant or having a positive urine pregnancy test
- Drug or alcohol use disorder
- End-stage organ disease, or other serious illnesses that would make the trial hard or unsafe
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Written informed consent to participate in the trial as prescribed
- Subjects with a weight of ≥50 kg and a body mass index between 18 and 40 kg/m2
- Diagnosed with IBS(C)-constipation, IBS(D)-diarrhea, or IBS(M)-mixed patients' diagnosis according to Rome Criteria (moderate to severe)
Who cannot take part
- Allergy to the investigational device or any components or clinically significant allergies (excluding mild seasonal allergies), in the opinion of the investigator
- Hospital admission or major surgery within 30 days prior to screening
- Participation in any other investigational drug trial within 30 days prior to screening
- Clinically relevant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or psychiatric disorders making implementation of the protocol or interpretation of the trial results difficult, or that would put the participant at risk by participating in the trial in the opinion of the Investigator
- Participant with substance use disorder (SUD) and/or alcohol use disorder (AUD)
- Participant who has other conditions that may affect compliance in the opinion of the investigator, or who are unable to participate in the trial on his/her own
- Participant with end stage organ disease
- Pregnant, or positive urine pregnancy test
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Where in United States
- UChicago Medicine AdventHealth Medical Group Gastroenterology at BolingbrookBolingbrook, United StatesContact: Hadi Saddiqui, DO, MPH (principal investigator)Taking people
- Central Florida Gastro ResearchKissimmee, United StatesContact: Muhammad Mohiuddin, MD (principal investigator)Taking people
- Delta Gastroenterology PCSouthhaven, United StatesContact: Ulric Duncan, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.
The group in the trial
- Pilot VCS CohortTreatment being tested
Wear VCS device for 6+ hours per day
Treatment: Variable Compression System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective Interventional Trial With a Non-invasive Variable Compression System (VCS) to Determine the Efficacy in Patients With Moderate to Severe Irritable Bowel Syndrome (IBS)
- Plain-language title
- Testing a wearable compression device for moderate to severe irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07540312, who can take part
- Record updated
- 29 April 2026